Doctors are not trained to communicate with patients. Now, with the onset of electronic medical records this problem has become worse. Many of them hardly even look their patient in the eyes; instead their faces are often buried in the computer screen and not on us. Since they don’t really know us, they stumble around, [...]
Recently there have been a number of conversations in the prostate media around the topic of treating oligometastatic prostate cancer with a curative goal. Oligometastatic prostate cancer describes the disease state where primary treatment has failed as evidenced by an increasing PSA along with scanning evidence of a limited number of lymph nodes involved in [...]
On Dec 2, 2014 Astellas Pharma Europe Ltd announced that the European Commission (EC) has granted a variation that amends their marketing authorization for enzalutamide (Xtandi). Based on this amended authorization Xtandi is now approved in Europe for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic [...]
On December 7, 2014 the TV show 60 Minutes (CBS) aired a very interesting story (narrated by Dr. Sanjay Gupta) interview about an amazing sounding man, Dr. Patrick Soon-Shing. To describe him as a genius would be an unfair understatement. Dr. Soon-Shing is a billionaire who has already invested about $1 billion dollars of his [...]
There has been much conversation surrounding the use of intermittent androgen deprivation (IAD) as opposed to continuous androgen deprivation (CAD) in men with prostate cancer who need hormone therapy (ADT). The question that has been at issue is if either method is superior to the other. There have been studies that have concluded that they [...]